Oric Pharmaceuticals (ORIC) Common Equity (2019 - 2026)

Oric Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $415.6 million for Q1 2026.

• Quarterly Common Equity rose 89.11% year-over-year to $415.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $415.6 million (up 89.11% YoY) and the FY2025 annual result came in at $384.4 million, up 58.09% from the prior year.
• Common Equity was $415.6 million for Q1 2026 at Oric Pharmaceuticals, up from $384.4 million in the prior quarter.
• Across five years, Common Equity topped out at $415.6 million in Q1 2026 and bottomed at $202.8 million in Q1 2023.
• A 5-year average of $280.5 million and a median of $253.1 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity sank 33.14% — and 2026, when it jumped 89.11%.
• Oric Pharmaceuticals' Common Equity stood at $222.4 million in 2022, then advanced by 0.78% to $224.1 million in 2023, then advanced by 8.49% to $243.1 million in 2024, then soared by 58.09% to $384.4 million in 2025, then gained by 8.12% to $415.6 million in 2026.
• Business Quant data shows ORIC's Common Equity at $415.6 million in Q1 2026, $384.4 million in Q4 2025, and $406.9 million in Q3 2025.